Perphenazine is a typical antipsychotic drug. Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the US as Trilafon, it has been in clinical use for decades. Perphenazine is roughly five times as potent as chlorpromazine, thus perphenazine is considered a medium-potency antipsychotic.

Scope of the Report:
The global average price of Perphenazine is in the decreasing trend, from 6.95 USD/Unit in 2012 to 7.08 USD/Unit in 2016. With the situation of global economy, prices will be in increasing trend in the following five years.

The classification of Perphenazine includes Oral Forms and Injectable Solution, and the proportion of Oral Forms in 2016 is about 98%.

Perphenazine is widely used to treat psychosis and antiemetic. The most proportion of Perphenazine is used to treat psychosis, and the proportion in 2016 is 95%.

North America is the largest consumption place, with a consumption market share nearly 39% in 2015. Following North America, Asia Pacific is the second largest consumption place with the consumption market share of 25%.

Market competition is not intense. Teva, Sandoz, Endo, Mylan, ZHPHARMA, Shandong Boshan Pharma, etc. are the leaders of the industry, with high-end customers; have been formed in the monopoly position in the industry.

The worldwide market for Perphenazine is expected to grow at a CAGR of roughly 0.7% over the next five years, will reach 100 million US$ in 2024, from 95 million US$ in 2019, according to a new study.
This report focuses on the Perphenazine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
Teva
Sandoz
Endo
Mylan
ZHPHARMA
Shandong Boshan Pharma

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Oral Forms
Injectable Solution

Market Segment by Applications, can be divided into
Psychosis
Antiemetic

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Perphenazine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Perphenazine, with price, sales, revenue and global market share of Perphenazine in 2017 and 2018.
Chapter 3, the Perphenazine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Perphenazine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Perphenazine market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Perphenazine sales channel, distributors, customers, research findings and conclusion, appendix and data source.